SCHEDULE 13G/A: RA Capital Entities Disclose 9.9% Stake in CervoMed Inc. Through Amended Schedule 13G Filing

RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. have jointly filed an amended Schedule 13G, disclosing a 9.9% beneficial ownership stake in CervoMed Inc. as of December 31, 2024.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") have filed an Amendment No. 1 to their Schedule 13G.
• The filing discloses that each Reporting Person beneficially owns 916,063 shares of CervoMed Inc.'s Common Stock, representing 9.9% of the class.
• This ownership percentage is based on 8,253,741 shares of Common Stock outstanding as of November 7, 2024, as reported in CervoMed's Form 10-Q filed on November 12, 2024, plus the 916,063 shares issuable upon warrant exercise.
• The RA Capital Healthcare Fund, L.P. holds warrants exercisable for up to 1,266,143 shares of Common Stock.
• A "Beneficial Ownership Blocker" provision in the warrants limits exercise to prevent the Fund and its affiliates from owning more than 9.99% of the Common Stock outstanding.
• Due to this blocker, the Fund is currently prohibited from exercising a portion of the warrants that would result in beneficial ownership of more than 916,063 shares.
• The Reporting Persons disclaim status as a "group" for purposes of this Schedule 13G and state that the securities were not acquired for the purpose of changing or influencing control of the issuer.
• RA Capital Management, L.P. serves as investment adviser for the Fund and has sole power to vote and dispose of the securities held by the Fund.
• Peter Kolchinsky and Rajeev Shah are controlling persons of RA Capital Management GP, LLC, the general partner of RA Capital, and may be deemed beneficial owners.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, which is neutral in sentiment. It indicates a significant, but passive, investment by a notable fund.

Positives

• The continued significant investment by RA Capital, a prominent healthcare-focused investment firm, indicates confidence in CervoMed Inc.'s long-term prospects.
• The disclosure provides transparency regarding a major institutional investor's stake in the company.

Negatives

• The presence of a "Beneficial Ownership Blocker" limits the ability of RA Capital to increase its stake beyond 9.99% through warrant exercise, potentially capping their influence or further investment via this mechanism.

Risks

• The "Beneficial Ownership Blocker" within the warrants limits the ability of RA Capital Healthcare Fund, L.P. to fully exercise its warrants if doing so would result in beneficial ownership exceeding 9.99% of CervoMed Inc.'s Common Stock outstanding.
• The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G, which could be a point of regulatory scrutiny if their actions were perceived as coordinated control-seeking.

Future Outlook

The document is a disclosure of current beneficial ownership and does not provide forward-looking statements or guidance regarding CervoMed Inc.'s operational or financial performance. It indicates a passive investment intent by the filers.

Industry Context

This filing indicates continued investment by a specialized healthcare fund (RA Capital) in CervoMed Inc., suggesting CervoMed operates within the biotechnology or pharmaceutical sector. Such disclosures are common for institutional investors taking significant, but passive, stakes in public companies.

Corporate Governance

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and potentially share price. The beneficial ownership blocker limits the extent of this investor's stake via warrants.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, RA Capital Management, CervoMed Inc., Common Stock, Warrants, Investment Fund, Healthcare Investment, SEC Filing, Institutional Investor, Biotech